Sanjita Ravishankar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sanjita Ravishankar has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Tulin Ozcan
Department of Obstetrics and Gynecology University Hospitals Cleveland Medical Center Cleveland Ohio USA
2 shared publications - Yi Yuan Zhou
Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA
2 shared publications Alicia A. Loehlein
Measure the Placenta, Shoreview, MN, USA
1 shared publicationAlison Migliori
Women & Infants Hospital of Rhode Island, Providence, RI, United States
1 shared publication- Anders Hagen Jarmund
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim (J.J.R., A.H.J., A.T.R.S., G.B.S., B.S., L.M.G., A.-C.I.).
1 shared publication - Ann-Charlotte Iversen
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim (J.J.R., A.H.J., A.T.R.S., G.B.S., B.S., L.M.G., A.-C.I.).
1 shared publication
Latest Publications
- Open Access
- 19 October 2026
- Published by Wolters Kluwer Health in Hypertension
sFlt-1 in Decidua, Placenta, and Maternal Serum in Preeclampsia Subtypes
BACKGROUND: Soluble FMS-like tyrosine kinase (sFlt-1) drives maternal symptoms in preeclampsia, serves as a predictive biomarker, and represents a promising therapeutic target. sFlt-1 is expressed in placental and decidual tissue, which together form the maternal-fetal interface. Whether placental and decidual expression of sFlt-1 regulates the maternal serum levels remains unknown. This study aimed to investigate sFlt-1 expression and co-regulation in decidua, placenta, and maternal serum, in normal pregnancies and preeclamptic pregnancies with and without fetal growth restriction. METHODS: Pregnant women with normal (n=65) or preeclamptic pregnancies with (n=42) or without (n=22) fetal growth restriction were included before cesarean delivery. sFlt-1 expression was quantified in maternal serum and umbilical cord blood (BRAHMS KRYPTOR) and by immunohistochemistry with semi-automated image analysis in decidual and placental tissue. RESULTS: Decidual and placental sFlt-1 expression was trophoblast-dependent and selectively upregulated in preeclampsia without and with fetal growth restriction, respectively, and maternal serum sFlt-1 was elevated in both preeclampsia subtypes ( P 11 500 pg/mL) only in preeclamptic pregnancies (n=21) and low levels (<11 500 pg/mL) in all normal pregnancies (n=28) and 42% (n=15) of preeclamptic pregnancies. CONCLUSIONS: sFlt-1 expression correlates across the maternal-fetal interface but is not directly reflected in maternal serum. The relationship to preeclampsia subtypes is complex.
- 19 October 2026
- Published by Wolters Kluwer Health in Hypertension
Open AccesssFlt-1 in Decidua, Placenta, and Maternal Serum in Preeclampsia Subtypes
BACKGROUND: Soluble FMS-like tyrosine kinase (sFlt-1) drives maternal symptoms in preeclampsia, serves as a predictive biomarker, and represents a promising therapeutic target. sFlt-1 is expressed in placental and decidual tissue, which together form the maternal-fetal interface. Whether placental and decidual expression of sFlt-1 regulates the maternal serum levels remains unknown. This study aimed to investigate sFlt-1 expression and co-regulation in decidua, placenta, and maternal serum, in normal pregnancies and preeclamptic pregnancies with and without fetal growth restriction. METHODS: Pregnant women with normal (n=65) or preeclamptic pregnancies with (n=42) or without (n=22) fetal growth restriction were included before cesarean delivery. sFlt-1 expression was quantified in maternal serum and umbilical cord blood (BRAHMS KRYPTOR) and by immunohistochemistry with semi-automated image analysis in decidual and placental tissue. RESULTS: Decidual and placental sFlt-1 expression was trophoblast-dependent and selectively upregulated in preeclampsia without and with fetal growth restriction, respectively, and maternal serum sFlt-1 was elevated in both preeclampsia subtypes ( P 11 500 pg/mL) only in preeclamptic pregnancies (n=21) and low levels (<11 500 pg/mL) in all normal pregnancies (n=28) and 42% (n=15) of preeclamptic pregnancies. CONCLUSIONS: sFlt-1 expression correlates across the maternal-fetal interface but is not directly reflected in maternal serum. The relationship to preeclampsia subtypes is complex.
- Open Access
- 15 May 2026
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 29 (5) , 479-492
Standardized Placental Pathology Reporting: Improving Quality and Clinical Utility Recommendations From the Society for Pediatric Pathology Placental Pathology Reporting Task Force
Background: Placental pathology has benefited greatly from the standardization of definitions provided by the Amsterdam consensus, however the quality of placental pathology reporting continues to suffer from a lack of unified and practical reporting standards and difficulty in applying the Amsterdam definitions to general clinical practice. Methods: A multidisciplinary Placental Pathology Reporting Task Force was formed to develop a standardized placental pathology reporting template based on a combination of evidence-based literature review and consensus expert opinion, and designed to complement the Amsterdam definitions. The goal of the task force was to create a practical, succinct, clinically informative, and easily customizable template that can be adapted to varying institutional preferences. Results: The proposed standardized reporting template encompasses a wide breadth of common placental pathologic diagnoses and provides recommended diagnostic terminology, explanatory comments and practical tips, and notes to ease the application of definitions. Input from pathologists from different practice settings, obstetric providers, neonatologists, and patient advocates was integrated. Conclusions: The introduction of a standardized placental reporting template holds the potential to reform and advance placental pathology practice across the diverse range of settings in which it is currently performed. The proposed template is adaptable, allowing pathologists to include additional information beyond the recommended standard as needed/preferred. Widespread adoption of this framework will enhance the clinical utility and value of placental pathology reports by clinicians and patients, ultimately supporting more informed and appropriate management of neonates and future pregnancies.
- 15 May 2026
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 29 (5) , 479-492
Open AccessStandardized Placental Pathology Reporting: Improving Quality and Clinical Utility Recommendations From the Society for Pediatric Pathology Placental Pathology Reporting Task Force
Background: Placental pathology has benefited greatly from the standardization of definitions provided by the Amsterdam consensus, however the quality of placental pathology reporting continues to suffer from a lack of unified and practical reporting standards and difficulty in applying the Amsterdam definitions to general clinical practice. Methods: A multidisciplinary Placental Pathology Reporting Task Force was formed to develop a standardized placental pathology reporting template based on a combination of evidence-based literature review and consensus expert opinion, and designed to complement the Amsterdam definitions. The goal of the task force was to create a practical, succinct, clinically informative, and easily customizable template that can be adapted to varying institutional preferences. Results: The proposed standardized reporting template encompasses a wide breadth of common placental pathologic diagnoses and provides recommended diagnostic terminology, explanatory comments and practical tips, and notes to ease the application of definitions. Input from pathologists from different practice settings, obstetric providers, neonatologists, and patient advocates was integrated. Conclusions: The introduction of a standardized placental reporting template holds the potential to reform and advance placental pathology practice across the diverse range of settings in which it is currently performed. The proposed template is adaptable, allowing pathologists to include additional information beyond the recommended standard as needed/preferred. Widespread adoption of this framework will enhance the clinical utility and value of placental pathology reports by clinicians and patients, ultimately supporting more informed and appropriate management of neonates and future pregnancies.
- 22 March 2022
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 46 (8) , 1036-1047
Diffuse and Localized SARS-CoV-2 Placentitis
Coronavirus disease 2019 (COVID-19) infection in pregnancy has been associated with preterm delivery and preeclampsia. A less frequent and underrecognized complication is extensive placental infection which is associated with high rates of perinatal morbidity and mortality. The frequency, early pathogenesis, and range of lesions associated with this infection are poorly understood. We conducted a population-based study of placental pathology from all mothers with COVID-19 (n=271) over an 18-month period delivering within our health system. The overall prevalence of diffuse severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) placentitis, as defined by typical histology and immunohistochemical (IHC) staining for SARS-CoV-2 spike protein, was 14.8/1000, but increased to 59/1000 in preterm births. We also identified 3 cases with isolated small foci of localized SARS-CoV-2 placentitis, characterized by focal perivillous fibrin and intervillositis, which illustrate the early pathogenesis and suggest that infection may be contained in some cases. Two other placental lesions were more common in mothers with COVID-19, high-grade maternal vascular malperfusion in preterm deliveries and high-grade chronic villitis at term (5/5 cases tested of the latter were negative by IHC for SARS-CoV-2). Additional investigation of diffuse and localized SARS-CoV-2 placentitis by IHC showed loss of BCL-2, C4d staining in surrounding villi, and an early neutrophil-predominant intervillous infiltrate that later became dominated by monocyte-macrophages. We propose a model of focal infection of syncytiotrophoblast by virally infected maternal leukocytes leading to loss of BCL-2 and apoptosis. Infection is then either contained by surrounding fibrinoid (localized) or initiates waves of aponecrosis and immune activation that spread throughout the villous parenchyma (diffuse).
- 22 March 2022
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 46 (8) , 1036-1047
Diffuse and Localized SARS-CoV-2 Placentitis
Coronavirus disease 2019 (COVID-19) infection in pregnancy has been associated with preterm delivery and preeclampsia. A less frequent and underrecognized complication is extensive placental infection which is associated with high rates of perinatal morbidity and mortality. The frequency, early pathogenesis, and range of lesions associated with this infection are poorly understood. We conducted a population-based study of placental pathology from all mothers with COVID-19 (n=271) over an 18-month period delivering within our health system. The overall prevalence of diffuse severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) placentitis, as defined by typical histology and immunohistochemical (IHC) staining for SARS-CoV-2 spike protein, was 14.8/1000, but increased to 59/1000 in preterm births. We also identified 3 cases with isolated small foci of localized SARS-CoV-2 placentitis, characterized by focal perivillous fibrin and intervillositis, which illustrate the early pathogenesis and suggest that infection may be contained in some cases. Two other placental lesions were more common in mothers with COVID-19, high-grade maternal vascular malperfusion in preterm deliveries and high-grade chronic villitis at term (5/5 cases tested of the latter were negative by IHC for SARS-CoV-2). Additional investigation of diffuse and localized SARS-CoV-2 placentitis by IHC showed loss of BCL-2, C4d staining in surrounding villi, and an early neutrophil-predominant intervillous infiltrate that later became dominated by monocyte-macrophages. We propose a model of focal infection of syncytiotrophoblast by virally infected maternal leukocytes leading to loss of BCL-2 and apoptosis. Infection is then either contained by surrounding fibrinoid (localized) or initiates waves of aponecrosis and immune activation that spread throughout the villous parenchyma (diffuse).
- Open Access
- 18 February 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (2) , 333
Pediatric Primary Hepatic Tumors: Diagnostic Considerations
The liver is the third most common site of abdominal tumors in children. This review article aims to summarize current evidence surrounding identification and diagnosis of primary hepatic tumors in the pediatric population based upon clinical presentation, epidemiology, and risk factors as well as classical imaging, histopathological, and molecular diagnostic findings. Readers will be able to recognize the features and distinguish between benign and malignant hepatic tumors within different age groups.
- 18 February 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (2) , 333
Open AccessPediatric Primary Hepatic Tumors: Diagnostic Considerations
The liver is the third most common site of abdominal tumors in children. This review article aims to summarize current evidence surrounding identification and diagnosis of primary hepatic tumors in the pediatric population based upon clinical presentation, epidemiology, and risk factors as well as classical imaging, histopathological, and molecular diagnostic findings. Readers will be able to recognize the features and distinguish between benign and malignant hepatic tumors within different age groups.
- 25 January 2021
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 24 (3) , 187-192
The Association of Fetal Congenital Cardiac Defects and Placental Vascular Malperfusion
Objectives: Abnormal early angiogenesis appears to impact both placental disorders and fetal congenital heart defects (CHD). We sought to assess the association of placental perfusion defects (PPD) and fetal (CHD). Methods: Singleton pregnancies with isolated severe fetal CHD were compared to controls without congenital anomalies or maternal malperfusion (MVM) risk factors. CHD was categorized into group 1: single left ventricle morphology and transposition of the great vessels (TGA) and group 2: single right ventricle and two ventricle morphology. Malperfusion was defined as fetal vascular malperfusion (FVM), MVM, and both FVM and MVM. Results: PPD was increased for all CHD (n = 47), CHD with or without risk factors, and CHD groups compared to controls (n = 92). Overall CHD cases and CHD with risk factors had an increased risk of FVM (30% and 80% vs 14%), and MVM (43% and 50% vs 21%), respectively. MVM rates were similar in CHD with and without maternal risk factors. FVM (38% vs 14%) and MVM (44% vs 21%) were increased in Group 1. MVM (42% vs 21%) and both FVM and MVM (16% vs 3%) were increased in Group 2. Conclusions: PPD risk is increased in severe isolated fetal CHD. The highest risk is seen in fetal CHD with maternal risk factors.
- 25 January 2021
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 24 (3) , 187-192
The Association of Fetal Congenital Cardiac Defects and Placental Vascular Malperfusion
Objectives: Abnormal early angiogenesis appears to impact both placental disorders and fetal congenital heart defects (CHD). We sought to assess the association of placental perfusion defects (PPD) and fetal (CHD). Methods: Singleton pregnancies with isolated severe fetal CHD were compared to controls without congenital anomalies or maternal malperfusion (MVM) risk factors. CHD was categorized into group 1: single left ventricle morphology and transposition of the great vessels (TGA) and group 2: single right ventricle and two ventricle morphology. Malperfusion was defined as fetal vascular malperfusion (FVM), MVM, and both FVM and MVM. Results: PPD was increased for all CHD (n = 47), CHD with or without risk factors, and CHD groups compared to controls (n = 92). Overall CHD cases and CHD with risk factors had an increased risk of FVM (30% and 80% vs 14%), and MVM (43% and 50% vs 21%), respectively. MVM rates were similar in CHD with and without maternal risk factors. FVM (38% vs 14%) and MVM (44% vs 21%) were increased in Group 1. MVM (42% vs 21%) and both FVM and MVM (16% vs 3%) were increased in Group 2. Conclusions: PPD risk is increased in severe isolated fetal CHD. The highest risk is seen in fetal CHD with maternal risk factors.
- 26 October 2020
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 24 (1) , 47-50
Massive Perivillous Fibrin Deposition in Congenital Cytomegalovirus Infection: A Case Report
Cytomegalovirus (CMV) infection is one of the most common congenital viral infections. Classically associated placental findings include chronic villitis with plasma cells, stromal hemosiderin deposition, and identification of viral inclusions in villous endothelial and stromal cells. We present a case of confirmed congenital CMV infection that lacked these classical findings, but demonstrated massive perivillous fibrin deposition (MPVFD). This is the first report of CMV associated with MPVFD. MPVFD is an uncommon placental lesion associated with adverse fetal outcomes and a high risk of recurrence. However, the recurrence risk in patients with an infectious cause may be lower in than patients with other associated clinical conditions.
- 26 October 2020
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 24 (1) , 47-50
Massive Perivillous Fibrin Deposition in Congenital Cytomegalovirus Infection: A Case Report
Cytomegalovirus (CMV) infection is one of the most common congenital viral infections. Classically associated placental findings include chronic villitis with plasma cells, stromal hemosiderin deposition, and identification of viral inclusions in villous endothelial and stromal cells. We present a case of confirmed congenital CMV infection that lacked these classical findings, but demonstrated massive perivillous fibrin deposition (MPVFD). This is the first report of CMV associated with MPVFD. MPVFD is an uncommon placental lesion associated with adverse fetal outcomes and a high risk of recurrence. However, the recurrence risk in patients with an infectious cause may be lower in than patients with other associated clinical conditions.
- 8 March 2020
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 23 (4) , 274-284
Predictors of High Grade and Other Clinically Significant Placental Findings by Indication for Submission in Singleton Placentas From Term Births
Indications for placental submission are variable. Established guidelines are largely based on expert opinion, and there is a need for more evidence-based criteria. A 10-year database of term placentas was used to evaluate indications significantly associated with placental pathology. Lesions in 5 categories were separated into high- and low-grade subgroups. Two additional high-grade lesions were also evaluated. Indications associated with high-grade placental lesions were chronic monitoring abnormalities, severe preeclampsia, pregestational diabetes, maternal signs of infection, postdates pregnancy, artificial reproductive technology, drug abuse, umbilical cord entanglements, selected gross placental abnormalities, stillbirth, Apgar 5 minutes <6, small-for-gestational age infant, and macrosomia. Indications for which placental findings did not differ from the population as a whole were acute monitoring abnormalities, chronic hypertension, maternal obesity, vaginal bleeding, accessory lobe/multilobed placenta, meconium-stained fluid, single umbilical artery, and borderline large-for-gestational age infant. Other indications for submission were intermediate showing significant or borderline elevations in the prevalence of low- and high-grade lesions combined. We suggest on the basis of this study that guidelines for the submission of singleton term placentas could be modified to exclude cases with clinical indications that lack a significant association with placental lesions.
- 8 March 2020
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 23 (4) , 274-284
Predictors of High Grade and Other Clinically Significant Placental Findings by Indication for Submission in Singleton Placentas From Term Births
Indications for placental submission are variable. Established guidelines are largely based on expert opinion, and there is a need for more evidence-based criteria. A 10-year database of term placentas was used to evaluate indications significantly associated with placental pathology. Lesions in 5 categories were separated into high- and low-grade subgroups. Two additional high-grade lesions were also evaluated. Indications associated with high-grade placental lesions were chronic monitoring abnormalities, severe preeclampsia, pregestational diabetes, maternal signs of infection, postdates pregnancy, artificial reproductive technology, drug abuse, umbilical cord entanglements, selected gross placental abnormalities, stillbirth, Apgar 5 minutes <6, small-for-gestational age infant, and macrosomia. Indications for which placental findings did not differ from the population as a whole were acute monitoring abnormalities, chronic hypertension, maternal obesity, vaginal bleeding, accessory lobe/multilobed placenta, meconium-stained fluid, single umbilical artery, and borderline large-for-gestational age infant. Other indications for submission were intermediate showing significant or borderline elevations in the prevalence of low- and high-grade lesions combined. We suggest on the basis of this study that guidelines for the submission of singleton term placentas could be modified to exclude cases with clinical indications that lack a significant association with placental lesions.
- Open Access
- 1 January 2020
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 222 (1) , S117-S118
162: Congenital cardiac defects and placental vascular malperfusion
- 1 January 2020
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 222 (1) , S117-S118
Open Access162: Congenital cardiac defects and placental vascular malperfusion
- 1 April 2017
- Published by Elsevier in Pathology - Research and Practice
- Vol. 213 (4) , 301-304
Placental findings in feto-maternal hemorrhage in livebirth and stillbirth
- 1 April 2017
- Published by Elsevier in Pathology - Research and Practice
- Vol. 213 (4) , 301-304
Placental findings in feto-maternal hemorrhage in livebirth and stillbirth
- 28 April 2016
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 43 (8) , 722-724
Giemsa is the optimal counterstain for immunohistochemical detection of BRAF V600E mutation status in pigmented melanomas
- 28 April 2016
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 43 (8) , 722-724
Giemsa is the optimal counterstain for immunohistochemical detection of BRAF V600E mutation status in pigmented melanomas